| 281.62 Delayed Data As of Sep 13 |  -2.56 / -0.90%Today’s Change | 271.57 Today|||52-Week Range 442.00 | -24.60% Year-to-Date |
| Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use Sep 13 / Zacks.com - Paid Partner Content | Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound? Sep 05 / Zacks.com - Paid Partner Content |
| Adverum Reports Data From Phase I Wet AMD Study, Stock Down Sep 13 / Zacks.com - Paid Partner Content | Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Sep 04 / Zacks.com - Paid Partner Content |
| Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe Sep 11 / Zacks.com - Paid Partner Content |
| Previous close | 284.18 |
| Today’s open | 283.84 |
| Day’s range | 279.47 - 287.00 |
| Volume | 617,113 |
| Average volume (3 months) | 800,636 |
| Market cap | $30.4B |
| Earnings growth (last year) | +100.98% |
| Earnings growth (this year) | +2.58% |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | +14.28% |
| P/E ratio | 15.6 |
| Price/Sales | 6.39 |
| Price/Book | 3.50 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALXNAlexion Pharmaceutic... | -0.86 | -0.79% |
| INCYIncyte Corp | +0.36 | +0.47% |
| VRTXVertex Pharmaceutica... | +2.49 | +1.44% |
| SGENSeattle Genetics Inc | -0.25 | -0.35% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | $6.31 |
| Annual revenue (last year) | $6.7B |
| Annual profit (last year) | $2.4B |
| Net profit margin | 36.42% |
Sector Health Technology |
Industry Biotechnology |
Co-President, Chief Executive Officer & Director Leonard S. Schleifer |
Co-President, Director & Chief Scientific Officer George Damis Yancopoulos |
Corporate headquarters Tarrytown, New York |
